BACKGROUND: Urine drug tests (UDTs) are recommended for patients on chronic opioid therapy (COT). Knowledge of the risk factors for aberrant UDT results could help optimize their use. OBJECTIVE: To identify primary care COT patient and opioid regimen characteristics associated with aberrant UDT results. DESIGN: Population-based observational. SAMPLE: 5,420 UDTs for Group Health integrated group practice COT patients. MEASURES: Group Health database measures of patient demographics, medical history, COT characteristics, and UDT results. RESULTS: Thirty percent of UDTs had aberrant results, including prescribed opioid non-detection (12.3 %), tetrahydrocannabinol (THC; 11.2 %), non-prescribed opioid (5.3 %), illicit drug (excluding THC; 0.6 %), nonprescribed benzodiazepine (1.7 %), and dilute (4.8 %). Adjusted odds ratios (95 % CI) of any aberrant result were higher for males than females CONCLUSIONS: In this primary care setting, results were aberrant for 30 % of UDTs of COT patients, largely because of prescribed opioid non-detection and THC. Aberrant results of almost all types were more likely among patients under the age of 45. Other risk factors varied across aberrancies, but commonly included current smoking and prior substance use disorder diagnosis.
INTRODUCTION
Epidemic levels of prescription opioid overdose, abuse, addiction, and diversion have followed dramatic increases in opioid prescribing for chronic non-cancer pain (CNCP) in the U.S. [1] [2] [3] [4] [5] [6] Chronic opioid therapy (COT) guidelines recommend urine drug tests (UDTs) to improve patient safety and reduce diversion. 2, [7] [8] [9] [10] [11] UDTs can help identify drug misuse/abuse (through detection of illicit drug, opioid, or benzodiazepine use unknown to the opioid prescriber) and diversion (a possibility when prescribed opioids are absent). However, little evidence exists regarding UDT use for various patient subgroups. 12 Guidelines vary in their recommendations, with two 9, 13 recommending mandatory testing for all COT patients, one advising testing for patients at risk for substance use disorders (SUDs), 8 and two 8, 14 commenting that screening low-risk populations increases false-positive results and is less costeffective. 11 Knowledge regarding the risk factors for aberrant results could help inform evidence-based recommendations regarding UDTs for COT monitoring.
We reported a substantial increase in UDTs for COT patients at Group Health's (GH) integrated group practice after implementation of a multifaceted opioid risk reduction initiative. 15 Illicit drug detection was rare, raising the question of whether UDTs should be targeted to patient subgroups based on risk for aberrancies. Little research has examined predictors of UDT results in the primary care COT population. In pain clinic and other settings, some studies found illicit drugs (including tetrahydrocannabinol [THC] ) to be more common among UDTs of males 16 and younger patients. 17, 18 Among veterans, UDT detection of illicit substances (including THC) was more common for those with SUD diagnoses. 19 Studies in diverse settings 18, 20 found no significant association between opioid regimen characteristics and UDT detection of illicit drugs.
The purpose of this study was to identify primary care COT patient and opioid regimen characteristics associated with aberrant UDT results. In the state of Washington, the setting of this study, use of marijuana is legal for chronic pain. We examined THC separately from illicit drugs. We hypothesized that illicit drug and THC use would be more common among younger patients, males, and patients with SUD history, and that prescribed opioid non-detection would be more common among patients with a history of SUD , on low-dose opioid therapy, and with less-than-daily opioid supply. Other analyses were exploratory.
METHODS

Study Setting and Sample
GH is a large nonprofit healthcare system in the state of Washington. GH patients are covered by individual, Medicare, Medicaid, state and federal employee, and employersponsored plans. The GH opioid risk reduction initiative, implemented in September 2010 in its integrated group practice, included COT patient care guidelines with UDT recommendations based on opioid dose and other risks (Text Box 1) as well as a pain management UDT. 15, 21 We identified all pain management UDTs performed January 2011-December 2012 for patients aged ≥20 years. We obtained UDT, pharmacy, and patient data from GH databases. To limit the sample to UDTs for CNCP patients, we excluded those of patients who, in the one-year period prior to the UDT, had had hospice care, opioid prescriptions from oncologists, or more than one visit for cancer other than non-melanoma skin cancer. To ensure data availability, we excluded UDTs for patients not continuously enrolled at GH for the previous year. We calculated patients' days' supply of transdermal and oral opioids (except buprenorphine) covering the 90 days before each UDT. We included only UDTs for patients on COT, defined by GH as ≥70 days' opioid supply in the prior 90 days. We compared characteristics of patients with UDTs in our sample to those of the overall population of GH COT patients who met study eligibility criteria on 1/1/2012, the study midpoint. This study was approved by the GH Institutional Review Board.
Measures
UDT Results. The GH pain management UDT (Text Box 2) i n c l u d e s a s c r e e n i n g i m m u n o a s s a y a n d l i q u i d chromatography-tandem mass spectrometry (LC-MS/MS) confirmatory test. Text Box 3 lists the LC-MS/MS results examined in the study. 28, 29 and use of short-acting opioids. 28 From GH databases, we obtained patient gender and age at the time of the UDT (and for all GH COT patients at the study midpoint), and International Classification of Diseases, 9th revision, clinical modification (ICD-9-CM) 34 patient visit diagnoses within the previous two years. We classified these diagnoses into clinically meaningful categories using Clinical Classifications Software (CCS). 35 We identified CCS alcohol and SUD diagnoses, and defined mental health diagnoses as any in the CCS categories of adjustment disorders, anxiety disorders, mood disorders, personality disorders, psychotic disorders, intentional self-inflicted injury, and some miscellaneous disorders (e.g., eating disorders; we excluded sexual and gender identity, somatoform, and sleep disorders). We identified current smokers as patients with electronic health record (EHR) flags indicating current tobacco use or prior-year visits with tobacco use disorder diagnoses (ICD-9-CM code 305.1). 36 For descriptive purposes, we used ICD-9-CM codes 37 to identify pain diagnoses for past-year visits.
We calculated the mean daily morphine-equivalent dose (MED) and total days' supply for opioid prescriptions (except buprenorphine) covering the 90-day period before each UDT (or study midpoint). 38 For multiple same-date prescriptions, we counted only the highest value of days' supply. We categorized days' supply as less than daily (70-83), daily/near daily (84-96), or excessive (≥97). We characterized patients' opioids over the 90 days as short-acting only, long-acting (recommended usual dosing frequency ≤3 times daily -fentanyl, levorphanol, methadone, and sustained-release formulations of hydromorphone, morphine, oxycodone, oxymorphone, tramadol, and tapentadol 39 ) only, or shortacting and long-acting.
Statistical Analysis
We conducted descriptive analyses, then logistic regression analyses predicting dilute samples and the following LC-MS/ MS UDT results (excluding dilute samples): (1) any aberrancy; (2) prescribed opioid non-detection (defined as negative for all opioids prescribed for prior 90 days); (3) THC but no illicit drug; (4) non-prescribed opioid; (5) illicit drug; and (6) non-prescribed benzodiazepine. To better understand the contributions of individual predictors, we entered all predictors in a multivariable model for each outcome that had sufficient counts for reliable results. Regression models were estimated using generalized estimating equations. 40, 41 We used an independence working correlation matrix and estimated standard errors using the robust sandwich estimator to account for dependence between some observations (multiple UDTs for some patients). 42 
RESULTS
Patient Characteristics
Among 10,405 pain management UDTs in 2011-2012 for patients aged ≥20 years, we excluded 3,183 because the patient had <70 days' opioid supply in the prior 90 days, 290 due to cancer exclusions, and 1,512 because the patient was not enrolled at GH for the prior year. The remaining 5,420 UDTs were performed for 3,809 patients. The study patient sample was similar to the overall GH COT patient population, albeit with more males and more patients under the age of 65, on long-acting opioids, and on moderate-high doses (Table 1) .
UDT Results
Aberrancies were observed in 30.6 % of the UDTs, including 12.3 % negative for all prescribed opioids, 11.2 % with THC, 5.3 % with non-prescribed opioids, 0.6 % with illicit drugs, 1.7 % with non-prescribed benzodiazepines, and 4.8 % dilute ( Table 2) . Examination of UDT results by patient and opioid characteristics indicates different patterns across different types of aberrancies (Table 3) .
Predictors of UDT Results
In multivariable analyses (Table 4) , adjusted odds ratios (AOR) and 95 % confidence intervals (CI) for any aberrant result were higher for males than females 
LC-MS/MS Result Definition Prescribed opioid nondetection
No detectable (detection threshold = 20 ng/ ml) amount of any opioid prescribed for the 90 days before the UDT. We excluded UDTs for patients for whom fentanyl, tramadol, or meperidine (not detected by LC-MS/MS) were the only opioids prescribed for the prior 90 days. THC (marijuana) Non-prescribed opioid Opioid for which patient had no prescription covering the 90 days prior to the UDT
Illicit drug
Non-prescribed amphetamine, methamphetamine, cocaine, PCP, MDMA (ecstasy), or 6-AM (heroin metabolite). We considered UDTs positive for illicit amphetamine only for patients with no prescriptions in the previous 90 days for stimulant medications detected as amphetamines.
Non-prescribed benzodiazepine
Benzodiazepine for which patient had no prescription covering the 90 days prior to the UDT Dilute sample 6-AM 6-acetylmorphine; LC-MS/MS liquid chromatography-tandem mass spectrometry; MDMA 3,4-methylenedioxymethamphetamine; PCP phencyclidine; THC tetrahydrocannabinol Note: When examining opioid non-detection or substance presence, we excluded tests in which opioid or substance absence could not be confirmed due to dilute sample. UDT urine drug test, COT chronic opioid therapy, MED morphine-equivalent dose * Patient characteristics are for the first UDT in the study period. The study sample of 5,420 UDTs reflected 3,809 unique patients. Among the first UDTs in the study period for these 3,809 patients, 60.6 % were for female patients. The median (interquartile range) =1 (1, 2) UDTs for each patient subgroup. Some percentages do not sum to 100 across variable categories due to rounding of decimals
DISCUSSION
Among UDTs performed in 2011-2012 for COT management of primary care patients in the integrated group practice of a large nonprofit healthcare system in the state of Washington, aberrant results were common (30.6 %), largely due to nondetection of prescribed opioids (12.3 % of UDTs) and detection of THC (11.2 %). Males, smokers, patients under the age of 45, and patients with prior SUD diagnoses had higher odds of aberrant results. Patients prescribed only short-acting opioids also had higher odds of aberrant results, apparently due to the greater likelihood of prescribed opioid non-detection. Patients on low opioid doses had higher odds of any aberrancy than those on moderate, but not high, doses. This may be explained by the findings that both moderate and high doses were negatively associated with one aberrancy (opioid nondetection), whereas only high dose was associated with another aberrancy, and this association was in the opposite direction (positive association with non-prescribed benzodiazepine). Cocaine, amphetamine, and methamphetamine were each detected in <0.5 % of the UDTs and consistent with general population estimates of their use. 43 No UDT detected ecstasy, PCP, or heroin. The last finding is unsurprising, given heroin's rapid metabolism and its estimated use by only 0.1 % of the general population. 43 This study extends prior knowledge regarding risk factors for aberrant UDTs. Most prior studies focused only on predictors of illicit drug detection and included THC with other illicit drugs. [16] [17] [18] [19] Our findings confirm the importance of younger age, SUD history, and smoking as risks for aberrancies, and reveal that risk factors vary across aberrancy types. In this setting, male gender predicted only THC detection; furthermore, history of mental health and alcohol use disorders (at least in the past two years) generally did not predict aberrancies.
As hypothesized, younger patients and patients with a history of SUD had greater odds of illicit drug detection. Low frequency of UDT illicit drug detection has also been reported for older patients in pain clinics. 17, 18 Patients with prior SUD diagnoses had almost three times greater odds of an illicit drug finding. Among Veterans Affairs healthcare network COT patients, the percentage of UDTs positive for illicit substances (including THC) was about three times higher for those with prior-year SUD diagnoses. 19 We found that smokers had over twice the odds of an illicit drug result. Little previous research has examined associations between smoking and chronic pain patient UDT results, although smoking is associated with opioid misuse/abuse among chronic pain patients 32, 33 and with illicit drug abuse in the general population. 44 Our hypothesis that males would have more illicit drug results was not confirmed; findings in previous studies were mixed. 16, 18 Consistent with prior studies, 18, 20 we found no significant association between opioid regimen characteristics and illicit drugs.
By far, the most common non-opioid substance detected was THC (11.2 % of UDTs), replicating findings in a study of veterans on COT. 20 Marijuana is the most commonly used recreational drug. 43 An estimated 7.3 % of the U.S. population uses marijuana, with approximately 7.6 million Americans using marijuana daily or almost daily. 43 Currently, 20 states (including Washington) plus the District of Columbia allow marijuana for medical use, and two states (including Washington) have legalized its recreational use. Associations have been reported between marijuana use and physical and mental health problems, 45 and between UDT detection of THC and opioid misuse, 23 but little is known concerning marijuana's effects on COT patient safety and outcomes. This is an important priority for future research.
As hypothesized, younger patients, males, and patients with a history of SUD had greater odds of THC detection. Adjusting for other characteristics, males and smokers had UDT urine drug test, COT chronic opioid therapy, MDMA 3,4-methylenedioxymethamphetamine (ecstasy), PCP phencyclidine, 6-AM 6-acetylmorphine (heroin metabolite), THC tetrahydrocannabinol (marijuana) Note: 12.3 % (634 of 5,162 UDTs) were positive for a benzodiazepine, with or without a recent prescription. * Aberrant result = illicit drug, non-prescribed benzodiazepine, nonprescribed opioid, THC, prescribed opioid non-detection, or dilute sample. The denominator is 5,387 because UDTs for 33 patients prescribed only fentanyl, meperidine, or tramadol (not detected by the UDT) in the prior 90 days were excluded (it is unknown whether the result would have been aberrant due to no opioid in the urine). Another 14 UDTs for patients prescribed only tramadol, meperidine, or fentanyl were classified as aberrant for another reason, so their UDTs were not excluded. † Excluding 43 UDTs because of inability to definitively confirm absence of opioids due to dilute sample and 43 UDTs for patients prescribed only fentanyl (n=8; another patient prescribed fentanyl had a dilute urine sample so was already excluded), tramadol (n=32; three others prescribed only tramadol were already excluded due to dilute samples), or meperidine (n=3) ‡ Excluding 258 UDTs because of inability to exclude presence of illicit drug, THC, or benzodiazepine due to dilute urine sample § Non-prescribed opioids: excluded 43 of the 5,420 UDTs because of dilute sample. ‖ Illicit drug = amphetamine (in a patient with no prescription filled in the prior 90 days for a stimulant medication that is detected as amphetamine in the UDT), cocaine, methamphetamine, 6-AM (heroin metabolite), MDMA (ecstasy), PCP approximately twice the odds and patients with prior SUD diagnoses had 1.6 times the odds of THC detection. It is unclear why patients with less-than-daily opioid supply also had higher odds; this may reflect patient preference for marijuana as a primary method for managing pain and/or physician reluctance to prescribe opioids daily for marijuana users. Non-prescribed opioids (detected in 5 % of UDTs) were more common among patients under the age of 45, consistent with previous findings of greater illicit drug use and opioid abuse among younger adults. 18, [22] [23] [24] [25] [26] [27] [28] [29] Excessive days' supply of prescribed opioids was also a risk factor, suggesting the importance of prescriber attention to total days' supply of prescribed opioids. The odds of having a non-prescribed opioid detected were over twice as great for African-Americans as for whites; further research is needed to explore possible reasons.
In 12.3 % of UDTs, no opioid prescribed in the prior 90 days was detected. While the detection threshold was quite low, extremely low opioid levels could have been missed. Prescribed opioid non-detection could reflect no opioid use in the time period allowing detection. Indeed, prescribed opioid non-detection was more common among patients with low opioid doses, less-than-daily opioid supply (versus daily/neardaily), and only short-acting opioid prescriptions. The same proportion of UDTs negative for prescribed opioids (12 %) was reported at an urban teaching hospital pain clinic. 18 Unlike our study, this result was not associated with opioid type or dose, although their patient sample was smaller and average dose was much higher. Opioid non-detection could also reflect diversion. In our study, prescribed opioid non-detection was more common among patients under the age of 45 or with prior SUD diagnoses -both risk factors for substance abuse. Bolded values indicate statistically significant at P<0.05. In predicting THC, the odds ratios in the multivariable model were slightly lower than in the bivariate analyses, but patterns of statistical significance were the same. In the multivariable regression analyses predicting prescribed opioid non-detection and dilute sample, results were similar to bivariate results, with the following minor exceptions:
In predicting prescribed opioid non-detection, current smoker and excessive days' supply were significant in the bivariate, but not the multivariable, models, and substance use disorder diagnosis was significant in the multivariable, but not the bivariate, model. For prediction of dilute samples, the ORs for days' supply 84-96 and ≥97 were significant relative to 70-83 in the bivariate, but not the multivariable, analyses. In each case, differences in ORs were minor, but minor differences in the 95 % CI resulted in changes in statistical significance.
*
Race and ethnicity could not be included in model predicting detection of illicit drugs due to insufficient subgroup sizes
UDTs negative for prescribed opioids require discussion between prescriber and patient to identify reasons and appropriate response. Benzodiazepines were detected in 12 % of UDTs; 1.7 % of UDTs detected benzodiazepines in patients without recent benzodiazepine prescriptions. Because benzodiazepines are associated with increased risk of opioid overdose, 46 UDTs have value for informing opioid prescribers previously unaware of concomitant benzodiazepine use.
Dilute urine samples, present in 4.8 % of tests, were significantly less common among men and African-Americans. Dilute urine may result from multiple causes (e.g., attempts to avoid drug detection, diuretic use, diet, fluid consumption, race, genetics), and requires interpretation by patients' physicians. 47 Regarding study limitations, the smoking and diagnosis information in the EHR may under-represent true rates of smoking and of mental health, alcohol use disorders, and other substance use disorders. The study was conducted in a single healthcare system, and most patients were on low-moderate opioid doses and on short-acting opioids only; results may not generalize to other settings. UDT aberrancies among COT patients are likely to be more common in pain clinics and other settings with a higher prevalence of substance abuse. Some patients may have obtained medications from non-GH pharmacies, but this would have been more expensive, and previous research indicates that GH members obtain nearly all of their prescription medications from GH pharmacies. 48 Study strengths include the large primary care population-based sample data on UDTs, patient diagnoses, and prescribed opioids, as well as the use of multivariable models to predict specific types of UDT aberrancies.
Our findings may be useful for making decisions with regard to UDT frequency and protocol for COT patients in settings with a low prevalence of drug abuse. The costs, physician and patient burden, rarity of illicit drug detection, ability of some patients to purposely avoid illicit drug detection, uncertainty regarding responses to aberrant results, and potential harms of UDTs (e.g., incorrectly assuming illicit drug use or diversion) must be weighed against potential benefits in deterrence of diversion or illicit drug use and in providing an objective reference of COT compliance, illicit drug use, and use of medications (e.g., non-prescribed opioids, benzodiazepines) that increase COT risks. Systematic reviews have noted the paucity (especially in primary care settings) and poor quality of studies of clinical outcomes associated with UDTs for COT patients. 2, [49] [50] [51] Clearly, more research is needed concerning the impact of UDTs on patient and public health safety and the cost-effectiveness of specific UDT guidelines in various settings. Different patient population scenarios may need different guidelines.
In the absence of adequate data, a policy of occasional random urine drug testing for all COT patients, with testing frequency based on known safety and abuse risk factors, might be reasonable. Physician prediction of individual patient risk for aberrant results is likely to be imprecise, and a policy of routine urine drug testing may be easier to administer, may mitigate the possible negative impact of selective UDTs on provider-patient relationships, and may discourage drug abusers from seeking COT. Our results suggest that it might be prudent to order UDTs more frequently for patients under the age of 45, smokers, and those with a history of SUD.
